紫杉醇联合洛铂化疗方案对宫颈癌患者血清SCCA、血清肿瘤相关物质、血管内皮生长因子水平的影响

Effects of paclitaxel combined with loplatin on serum SCCA,serum tumor-related substance(TAM)and vascular endothelial growth factor levels in patients with cervical cancer

目的:探讨紫杉醇联合洛铂化疗方案对宫颈癌患者血清鳞状上皮细胞癌抗原(Squamous cell carcinoma antigen,SCCA)、血清肿瘤相关物质(Tumor associated material,TAM)、血管内皮生长因子水平(Vascular endothelial growth factor,VEGF)的影响。方法:选取2020年10月至2022年10月于我院接受化疗的82例宫颈癌患者作为研究对象,采用随机数字表法分为对照组与观察组,各41例。对照组采取奈达铂联合紫杉醇术前新辅助化疗,观察组采取洛铂联合紫杉醇术前新辅助化疗。分析比较两组的治疗效果,血清SCCA、TAM、VEGF水平、药物不良反应以及患者满意度。结果:观察组患者总有效率明显高于对照组(P<0.05)。治疗后,两组的血清SCCA、TAM、VEGF水平均明显降低,且观察组的血清SCCA、TAM、VEGF水平均明显低于对照组(P<0.05)。两组的不良反应发生率无明显差异(P>0.05)。观察组总满意度明显高于对照组(P<0.05)。结论:洛铂联合紫杉醇在宫颈癌临床化疗上效果较好,能有效改善血清SCCA、TAM、VEGF水平,药物不良反应较轻。

Objective:Objective To investigate the effects of paclitaxel combined with loplatin on serum Squamous cell carcinoma antigen(SCCA)and serum Tumor associated material(Tumor associated material)in patients with cervical cancer.TAM and Vascular endothelial growth factor(VEGF)levels were associated with endothelial growth factor.Methods:A total of 82 patients with cervical cancer who received chemotherapy in our hospital from October 2020 to October 2022 were selected as research objects and divided into control group and observation group by random number table method,with 41 cases in each group.The control group received nedaplatin combined with paclitaxel preoperative neoadjuvant chemotherapy,the observation group received loplatin combined with paclitaxel preoperative neoadjuvant chemotherapy.The therapeutic effects,serum SCCA,TAM,VEGF levels,adverse drug reactions and patient satisfaction of the two groups were analyzed and compared.Results:The total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,the serum levels of SCCA,TAM and VEGF in both groups were significantly decreased,and the serum levels of SCCA,TAM and VEGF in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total satisfaction of the observation group was significantly higher than that of the control group(P<0.05).Conclusion:Loplatin combined with paclitaxel can effectively improve the levels of serum SCCA,TAM and VEGF in the treatment of cervical cancer,and the drug side effects are mild.